NANOFACTS Recognized as EU-Funded Cancer Research Success Story

We are excited to announce that the European Commission has officially recognized the NANOFACTS project as a success story in the field of EU-funded cancer research.

Supported by Horizon Europe and driven by strong collaborations with Trinity College Dublin and TU Wien, the BioSense Institute has made significant strides in advancing cancer diagnostics and treatment technologies.

Key Innovations Include:

  • Targeted therapy for glioblastoma multiforme — one of the most aggressive brain cancers — using chlorotoxin derived from scorpion venom, in combination with nanoparticles and MRI-guided delivery. This approach brings us closer to highly personalized and effective cancer treatments.

  • Development of advanced biosensors for early cancer detection, focused on biomarkers such as HER-2 and MMP-2, enabling more accurate, rapid, and accessible diagnostics.

We are proud to be pushing the boundaries of biomedical research and contributing to the future of personalized oncology.

👉 Read the full story on the European Commission website